Publicaciones científicas

Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor

03-abr-2021 | Revista: Transfusion and Apheresis Science

M Luisa Antelo  1 , Ane Altuna  2 , J José Gimeno  3 , J Javier Ferreiro  4 , Cristina Amunárriz  5 , J José Mateos  6 , Saioa Zalba  7 , Aitziber Alkorta  8 , José Rifón  9 , J Luis Arroyo  10 , Amaia Uresandi  11 , J Antonio Moreno  12 , M Josefa Nájera  13 , Sergio Pinzón  14 , Alejandro García  15 , J Carlos Vallejo  16 , Northern Spanish Working Group for Hematopoietic stem cell mobilization and transplantation


Plerixafor (PLX) appears to effectively enhance hematopoietic stem-cell mobilization prior to autologous hematopoietic stem cell transplantation (auto-HCT). However, the quality of engraftment following auto-HCT has been little explored.

Here, engraftment following auto-HCT was assessed in patients mobilized with PLX through a retrospective, multicenter study of 285 consecutive patients. Information on early and 100-day post-transplant engraftment was gathered from the 245 patients that underwent auto-HCT.

The median number of PLX days to reach the stem cell collection goal (≥2 × 106 CD34+ cells/kg) was 1 (range 1-4) and the median PLX administration time before apheresis was 11 h (range 1-18). The median number of apheresis sessions to achieve the collection goal was 2 (range 1-5) and the mean number of CD34+ cells collected was 2.95 × 106/kg (range 0-30.5). PLX administration was safe, with only 2 mild and transient gastrointestinal adverse events reported.

The median time to achieve an absolute neutrophil count (ANC) >500/μL was 11 days (range 3-31) and the median time to platelet recovery >20 × 103/μL was 13 days (range 5-69). At 100 days after auto-HCT, the platelet count was 137 × 109/L (range 7-340), the ANC was 2.3 × 109/L (range 0.1-13.0), and the hemoglobin concentration was 123 g/L (range 79-165).

PLX use allowed auto-HCT to be performed in a high percentage of poorly mobilized patients, resulting in optimal medium-term engraftment in the majority of patients in whom mobilization failed, in this case mainly due to suboptimal peripheral blood CD34+ cell concentration on day +4 or low CD34+ cell yield on apheresis.

CITA DEL ARTÍCULO  Transfus Apher Sci. 2021 Apr 3;103130.  doi: 10.1016/j.transci.2021.103130

Nuestros autores